Phenomenex to be Acquired by Danaher Corporation
Phenomenex has announced that it will be acquired by Danaher Corporation, a Fortune 150 science and technology company. Phenomenex will continue to operate as a standalone company, and will retain the Phenomenex brand, its personnel, and site locations.
Phenomenex (Torrance, California, USA) has announced that it will be acquired by Danaher Corporation (Washington, D.C., USA), a Fortune 150 science and technology company. Phenomenex will continue to operate as a standalone company, and will retain the Phenomenex brand, its personnel, and site locations.
“Phenomenex is a widely recognizable brand that we are proud to say is highly respected and well established as providing high-quality consumables to the scientific community worldwide,” said Fasha Mahjoor, CEO of Phenomenex. “Joining Danaher will allow us to maintain the high pace of innovation that our customers and international distributors have come to expect from us. This is our opportunity to further expand our R&D activities, benefit our customers with a more diversified product portfolio, and reinforce our market leadership.”
Phenomenex employees more than 700 people worldwide and provides support into 92 countries through direct and distributor channels.
“We are thrilled to have Phenomenex join Danaher’s life sciences portfolio of businesses, which include Sciex, Beckman Coulter Life Sciences, Pall, Leica Microsystems, and Molecular Devices,” said Dan Daniel, Executive Vice President of Danaher. “The Danaher Business System (DBS) has a strong track record of helping businesses rapidly scale operations and create long-term customer value. We look forward to supporting the Phenomenex team in leveraging DBS tools for growth and welcoming them to our Life Sciences team.”
The transaction is expected to close by late 2016. For more information, please visit www.phenomenex.com or www.danaher.com
AI and GenAI Applications to Help Optimize Purification and Yield of Antibodies From Plasma
October 31st 2024Deriving antibodies from plasma products involves several steps, typically starting from the collection of plasma and ending with the purification of the desired antibodies. These are: plasma collection; plasma pooling; fractionation; antibody purification; concentration and formulation; quality control; and packaging and storage. This process results in a purified antibody product that can be used for therapeutic purposes, diagnostic tests, or research. Each step is critical to ensure the safety, efficacy, and quality of the final product. Applications of AI/GenAI in many of these steps can significantly help in the optimization of purification and yield of the desired antibodies. Some specific use-cases are: selecting and optimizing plasma units for optimized plasma pooling; GenAI solution for enterprise search on internal knowledge portal; analysing and optimizing production batch profitability, inventory, yields; monitoring production batch key performance indicators for outlier identification; monitoring production equipment to predict maintenance events; and reducing quality control laboratory testing turnaround time.
2024 EAS Awardees Showcase Innovative Research in Analytical Science
November 20th 2024Scientists from the Massachusetts Institute of Technology, the University of Washington, and other leading institutions took the stage at the Eastern Analytical Symposium to accept awards and share insights into their research.
